Login to Your Account



Other News To Note


Thursday, February 10, 2011
Neuralstem Inc., of Rockville, Md., announced the FDA granted orphan drug designation for the treatment of amyotrophic lateral sclerosis (ALS) to its human spinal cord-derived neural stem cells, NSI-566RSC, currently in a Phase I study to evaluate the safety of the product and the surgical route of administration in a wide range of ALS patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription